Adcock Ingram shares rise after securing state HIV drug contract
The pharmaceuticals group said its investment in local manufacturing facilities has paid off
Pharmaceuticals group Adcock Ingram’s share price rose as much as 6.3% to R69.12 on Monday morning after issuing a statement saying how much of the government’s antiretroviral medicine contract it had won. Adcock Ingram said it will supply 12% of the antiretroviral drugs state hospitals will purchase over the next three years, equating to R1.8bn excluding VAT.
“Our investment into the oral solid dosage facility situated in Wadeville has increased our ability to manufacture and supply antiretroviral medicines to the public sector through the tender system, and also meet the needs of the private healthcare market,” Adcock Ingram prescription division MD Ashley Pearce said in a media release. The local medicine manufacturer said it submitted bids for two triple combination products — Tenofovir, Emtricitabine, Efavirenz (TEE), and Dolutegravir, Lamivudine, Tenofovir (DLT) — as well as a number of the dual- and monotherapy molecules. Its share of the antiretroviral tender award ove...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.